GeoVax Labs Inc. (NASDAQ:GOVX) Sees Significant Increase in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 470,940 shares, a growth of 85.2% from the April 30th total of 254,323 shares. Approximately 13.6% of the shares of the stock are sold short. Based on an average trading volume of 835,393 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On GeoVax Labs

Hedge funds have recently made changes to their positions in the business. Sabby Management LLC bought a new position in shares of GeoVax Labs during the third quarter valued at $313,000. Hudson Bay Capital Management LP bought a new position in shares of GeoVax Labs during the third quarter valued at $47,000. Jane Street Group LLC bought a new position in shares of GeoVax Labs during the first quarter valued at $27,000. Renaissance Technologies LLC bought a new position in shares of GeoVax Labs during the fourth quarter valued at $104,000. Finally, Armistice Capital LLC bought a new position in shares of GeoVax Labs during the third quarter valued at $253,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock opened at $2.21 on Tuesday. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $34.75. The firm has a market cap of $7.68 million, a PE ratio of -0.12 and a beta of 3.36. The stock has a fifty day moving average price of $1.61 and a 200-day moving average price of $3.81.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that GeoVax Labs will post -8.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GOVX has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.